contributor

Hogan Mullally

The Latest From Hogan Mullally

Analysts Life Sciences tst

Telesta Therapeutics has a date with FDA destiny

Analysts Life Sciences vrx

Is Bill Ackman right about Valeant Pharmaceuticals?

Life Sciences

Tekmira: Goodbye Old Friend

Analysts Life Sciences tkm

What Does the Future Hold for Tekmira’s Ebola Program?

Analysts Life Sciences ops

A Regulatory Hat-Trick: Opsens OptoWire Cleared for Sale in Japan, Europe, and now U.S

Analysts Life Sciences mph

Medicure is Persevering on the Prairies

Analysts Life Sciences th

Theratechnologies Is Reinventing Itself

Analysts Life Sciences onc

Oncolytics Biotech and Orphan Drug Designations: Wash, Rinse, Repeat

Life Sciences pli

Prometic Life Sciences should have strong clinical news flow in 2015

tos

TSO3 Goes it Alone. But For How Long?

Life Sciences tkm

Meet the new billion dollar Tekmira

Life Sciences tos

TS03 Gives Investors an Early Christmas Present

Life Sciences pli

Prometic Plans to Move Quickly With Rare Disease Candidate

Life Sciences tos

TSO3 Awaits FDA Verdict After Label Submission

Analysts Life Sciences ops

Sensing An Opportunity: Opsens Poised To Enter Growing Cardiac Market

Life Sciences bnc

Bioniche Extends Cash Runway In Advance of FDA Decisions & Submissions

Life Sciences onc

Oncolytics Slides After Pancreatic Study Results

Life Sciences rx

BioSyent Keeps Momentum Going with Solid Q2 Earnings

Analysts Life Sciences tos

TS03 Shares Spike On Anticipation of FDA Approval

Life Sciences gud

What does BioMarin’s voucher sale mean to Knight Therapeutics?

Life Sciences bnc

Investors awaken to the potential of newly focused Bioniche Life Sciences

Life Sciences

Is Concordia Healthcare The Next Canadian Tax Inversion Target?

Analysts Life Sciences aup cth cxr dma gud imv lor ndq sss tmd

Canadian Biotech is Healthy, Regardless of Financing Climate

Analysts Life Sciences gud plb

Investors follow Paladin’s Goodman to Knight Therapeutics

Analysts Life Sciences rx

Is BioSyent The Next Paladin Labs?

Analysts Life Sciences tkm

How Tekmira Became Canada’s Hottest Biotech Stock

Share

Tweet

Share

Get Stock Picks from the Pros. In your Inbox.